Swedish neurotech startup Flow Neuroscience has secured FDA approval for the first brain stimulation device for home use in ...

In a major shift for how mental health conditions might be treated, the US Food and Drug Administration (FDA) has approved ...

< Visual representation of brain regions with significant between-group differences in node persistenc ...

It is a central question in neuroscience to understand how different regions of the brain interact, how strongly they "talk" ...

Begin the new year by supporting your body's microbiome with Invivo. As you enter a season of renewal, nurturing your ...

Explore therapeutic choices for patients with treatment-resistant depression, including ketamine, psilocybin, and various ...

The US FDA has approved the FL-100, the first at-home brain-stimulation device for treating moderate to severe major depressive disorder, following successful trials.

One company that’s looking into ways the symptoms of your cycle are shaped by the brain is Samphire Neuroscience. Our brain’s ...

The FDA has approved the first at -home brain-stimulation device for adults with major depressive disorder (MDD). The FL-100 transcranial direct-current stimulation (tDCS) system (Flow Neuroscience) ...

The FDA on Thursday approved a transcranial direct current stimulation (tDCS) device as the first at-home non-drug therapy for major depression in adults, maker Flow Neuroscience announced. Dubbed ...

In a first, this week the U.S. Food and Drug Administration approved a brain stimulation device designed to treat depression at home. The approval of the first such device for home depression ...

The FDA has approved Flow, a prescription home-use cranial electrotherapy stimulation device, for treating moderate to severe major depressive disorder (MDD) in adults aged 18 years and older.